Objective: Venous thromboembolism (VTE) is a serious multifactorial disorder. Patients with severe mental illness have a higher risk of developing the condition compared to the general population. Methods: We observed 10 cases of VTE in patients with mental illness who were treated with the antipsychotic drug olanzapine. The diagnosis of VTE was made at the University Hospital Hradec Kralove (UH HK) from 2004 to 2013. VTE was objectively determined by imaging techniques (duplex ultrasonography, CT angiography) and laboratory tests (D-dimer). The average age was 46 years. The clinical manifestation of VTE was deep vein thrombosis in nine cases, including one case of simultaneous pulmonary embolism and one case of a concurrent ischemic cerebrovascular accident (iCVA). None of our patients had a history of malignant disease, trauma, or surgery. Results: Apart from antipsychotic medication, all the patients had clinical or laboratory risk factors for VTE. The most frequent clinical risk factors were obesity (n = 7) and smoking (n = 6). The most frequent laboratory risk factors were increased levels of FVIII (n = 4), mild hyperhomocysteinemia (n = 3), and factor V Leiden mutation (n = 2). VTE developed within 3 months after antipsychotic drug initiation in three patients and within 6 months in three patients. Conclusion: Olanzapine can be considered a precipitating factor for VTE formation. When olanzapine is administered, we need to monitor for clinical signs and symptoms of VTE, especially when other risk factors are present.

Biomedical Research Center University Hospital Hradec Kralove Hradec Kralove Czechia

Department of Chemistry Faculty of Science University of Hradec Kralove Hradec Kralove Czechia

Department of Neurology Charles University Prague Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove Czechia

Department of Psychiatry Charles University Prague Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove Czechia

Zobrazit více v PubMed

Di Nisio M, van Es N, Buller HR. Deep vein thrombosis and pulmonary embolism. Lancet (2016) 388:3060–73. 10.1016/S0140-6736(16)30514-1 PubMed DOI

Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis (2016) 41:3–14. 10.1007/s11239-015-1311-6 PubMed DOI PMC

Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Berqvist D, Brecht JG, et al. Venous thromboembolism (VTE) in Europe. Thromb Haemost (2007) 98:756–64. 10.1160/TH07-03-0212 PubMed DOI

Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis—current understanding from an epidemiological point of view. Br J Haematol (2010) 149:824–33. 10.1111/j.1365-2141.2010.08206.x PubMed DOI

Masopust J, Maly R, Andrys C, Valis M, Bazant J, Hosak L. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry (2011) 11:2. 10.1186/1471-244X-11-2 PubMed DOI PMC

Masopust J, Maly R, Andrys C, Valis M, Bazant J, Hosak L. The dynamics of haemostatic parameters in acute psychotic patients: a one-year prospective study. Psychiatr Danub (2013) 25:142–8. PubMed

Khandaker GM, Cousins L, Deakin J, Lennox BR, Yolken R, Jones PB. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry (2015) 2:258–70. 10.1016/S2215-0366(14)00122-9 PubMed DOI PMC

Hagg S, Bate A, Stahl M, Spigset O. Associations between venous thromboembolism and antipsychotics. Drug Saf (2008) 31:685–94. 10.2165/00002018-200831080-00005 PubMed DOI

Jonsson AK, Schill J, Olsson H, Spigset O, Hagg S. Venous thromboembolism during treatment with antipsychotics: a review of current evidence. CNS Drugs (2018) 32:47–64. 10.1007/s40263-018-0495-7 PubMed DOI PMC

Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf (2014) 37:79–90. 10.1007/s40264-013-0127-6 PubMed DOI

Zhang R, Dong L, Shao F, Tan X, Ying K. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry (2011) 44:183–8. 10.1055/s-0031-1280814 PubMed DOI

Masopust J, Maly R, Valis M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci (2012) 66:541–52. 10.1111/pcn.12001 PubMed DOI

Wu CS, Lin CC, Chang CM, Wu KY, Liang HY, Huang YW, et al. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J Clin Psychiatry (2013) 74:918–24. 10.4088/JCP.12m08117 PubMed DOI

Ishiguro C, Wang X, Li L, Jick S. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case–control study using the CPRD. Pharmacoepidemiol Drug Saf (2014) 23:1168–75. 10.1002/pds.3699 PubMed DOI

Shulman M, Njoku IJ, Manu P. Thrombotic complications of treatment with antipsychotic drugs. Minerva Med (2013) 104:175–84 PubMed

Kamijo Y, Soma K, Nagai T, Kurihara K, Ohwada T. Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J (2003) 67:46–8. 10.1253/circj.67.46 PubMed DOI

Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematol Am Soc Hematol Educ Program (2005) 2005:1–12. 10.1182/asheducation-2005.1.1 PubMed DOI

Bhanji NH, Chouinard G, Hoffman L, Margolese HC. Seizures, coma, and coagulopathy following olanzapine overdose. Can J Psychiatry (2005) 50:126–7. 10.1177/070674370505000214 PubMed DOI

Wallaschofski H, Eigenthaler M, Kiefer M, Donne M, Hentschel B, Gertz HJ, et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol (2003) 23:479–83. 10.1097/01.jcp.0000088914.24613.51 PubMed DOI

Borch KH, Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromso study. J Thromb Haemost (2009) 7:739–45. 10.1111/j.1538-7836.2008.03234.x PubMed DOI

Christiansen SC, Lijfering WM, Naess IA, Hammerstrom J, van Hylckama Vlieg A, Rosendaal FR, et al. The relationship between body mass index, activated protein C resistance and risk of venous thrombosis. J Thromb Haemost (2012) 10:1761–7. 10.1111/j.1538-7836.2012.04828.x PubMed DOI

Morange PE, Alessi MC. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb Haemost (2013) 110:669–80. 10.1160/TH13-01-0075 PubMed DOI

Hem E, Steen O, Opjordsmoen S. Thrombosis associated with physical restraints. Acta Psychiatr Scand (2001) 103:73–5. 10.1034/j.1600-0447.2001.00082.x PubMed DOI

Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case–control study. BMJ (2010) 341:c4245. 10.1136/bmj.c4245 PubMed DOI

De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. World Psychiatry (2011) 10:52–77. 10.1002/j.2051-5545.2011.tb00014.x PubMed DOI PMC

Maly R, Masopust J, Hosak L, Konupcikova K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci (2008) 62:3–8. 10.1111/j.1440-1819.2007.01773.x PubMed DOI